S-Space College of Medicine/School of Medicine (의과대학/대학원) Program in Cancer Biology (협동과정-종양생물학전공) Journal Papers (저널논문_협동과정-종양생물학전공)
Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM(197) protein conjugate; Prevenar ) in Korean infants: differences that are found in Asian children
- Kim, Nam-Hee; Lee, Jina; Lee, Sang Jeong; Lee, Hyunju; Kim, Kyung-Hyo; Park, Su-Eun; Lee, Hoan-Jong
- Issue Date
- Vaccine 2007;25(45):7858-65
- Antibody Formation/*immunology; Asia; Dose-Response Relationship, Immunologic; Humans; Immunization; Infant; Korea/epidemiology; Meningococcal Vaccines/administration & dosage/adverse effects/*immunology; Pneumococcal Vaccines/administration & dosage/adverse effects/*immunology; *Safety; Vaccines, Combined/adverse effects/immunology; Vaccines, Conjugate/*administration & dosage/*immunology
- This study was conducted to determine the immunogenicity and safety of a 7-valent CRM197 protein conjugated pneumococcal vaccine (PCV7) in Korean infants immunized at 2, 4 and 6 months. A total of 202 infants were enrolled and 146 and 141 infants were, respectively, included in post-2nd dose and post-3rd dose immunogenicity evaluations conducted on a per protocol basis. After two and three PCV7 vaccinations, 63.0-98.0 and 97.2-100% of infants achieved an antibody level of >or=0.35microg/mL, respectively, with a lowest against serotype 6B. No vaccination-related serious adverse reactions were observed. Thus, PCV7 appears safe and highly immunogenic in Korean infants, and adopting two doses for a primary series could be a feasible option for facilitating vaccine coverage rate.
- 0264-410X (Print)
- Files in This Item: There are no files associated with this item.